Gregory Otterson
Medical Oncology
Credentials: · ·
History
- 1989–1992
Hematology and Medical Oncology
- 1986–1989
Internal Medicine
Research
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
New England Journal of Medicine · 2018 · 2,498 citations
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 1,255 citations
The Lancet Oncology · 2015 · 1,216 citations
- MV
49 papers
37 papers · 4 as a fellow
- EB
29 papers · 5 as a fellow
28 papers
- DE
25 papers
23 papers
22 papers
- GR
22 papers
Grants
- 1997–2025
National Cancer Institute · P30
Project lead · $894K · Ohio State University
- 2002–2005
PREOPERATIVE TREATMENT OF LUNG CANCER WITH rhuMab VEGF
National Cancer Institute · R21
Contact PI · $656.1K · Ohio State University
Clinical trials
- 2011–2012
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
- 2008–2011
Principal investigator · Completed · Phase 2
Greg Otterson
- 2004
Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
- 2004
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)